^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    famitinib (SHR 1020)

    i
    Other names: SHR 1020, SHR-1020, SHR1020
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    Multi-tyrosine kinase inhibitor
    Related drugs:
    5d
    FUSCC Refractory TNBC Platform Study (FUTURE2.0) (clinicaltrials.gov)
    P2, N=120, Recruiting, Fudan University
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    everolimus • AiRuiKa (camrelizumab) • trastuzumab rezetecan (SHR-A1811) • famitinib (SHR 1020)
    21d
    Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=160, Recruiting, Fudan University | N=120 --> 160
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HR positive
    |
    trastuzumab rezetecan (SHR-A1811) • famitinib (SHR 1020) • SHR-A2102 • bulumtatug fuvedotin (9MW2821) • ruzaltatug rezetecan (SHR-A2009) • tizetatug rezetecan (SHR-A1921)
    26d
    A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Jin LI
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020)
    2ms
    Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype (clinicaltrials.gov)
    P3, N=248, Not yet recruiting, Fudan University
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression • PGR positive
    |
    trastuzumab rezetecan (SHR-A1811) • famitinib (SHR 1020)
    2ms
    Adebrelimab and famitinib alone or combined with short-course chemotherapy as the first-line treatment for PD-L1-positive advanced non-small cell lung cancer: a clinical study (ChiCTR2500115247)
    P4, N=80, Not yet recruiting, Changzhou First People's Hospital; Changzhou First People's Hospital
    New P4 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK rearrangement
    |
    famitinib (SHR 1020) • AiRuiLi (adebrelimab)
    3ms
    A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer (clinicaltrials.gov)
    P2, N=104, Not yet recruiting, Qinglei Gao
    New P2 trial
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    AiRuiYi (fluzoparib) • retlirafusp alfa (SHR-1701) • famitinib (SHR 1020)
    3ms
    Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy (clinicaltrials.gov)
    P2, N=66, Recruiting, Shandong Tumor Hospital
    New P2 trial
    |
    irinotecan • famitinib (SHR 1020) • AiRuiLi (adebrelimab)
    5ms
    Exploring the efficacy and safety of famitinib combined with epalrestat and torivirine in the treatment of advanced and recurrent/metastatic cervical cancer (ChiCTR2500111354)
    P2, N=90, Not yet recruiting, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    famitinib (SHR 1020) • iparomlimab (QL1604)
    5ms
    A prospective, multicenter, phase II study of famitinib maleate combined with camrelizumab and chemotherapy as neoadjuvant therapy for locally advanced cervical cancer. (ChiCTR2500109134)
    P2, N=60, Not yet recruiting, Fujian Cancer Hospital; Fujian Cancer Hospital
    New P2 trial
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020)
    7ms
    A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. (clinicaltrials.gov)
    P3, N=48, Terminated, Jiangsu HengRui Medicine Co., Ltd. | N=560 --> 48 | Trial completion date: Oct 2023 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Aug 2025; Terminated by Sponsor
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement
    |
    carboplatin • AiRuiKa (camrelizumab) • pemetrexed • famitinib (SHR 1020)
    7ms
    Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer (clinicaltrials.gov)
    P3, N=443, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Apr 2025 --> May 2027
    Trial completion date
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020)
    7ms
    CASTLE-ZS-03: Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma. (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Fudan University
    New P2 trial
    |
    retlirafusp alfa (SHR-1701) • famitinib (SHR 1020)